Search the Newsreel

Dr. Reddy's launches sugammadex injection

Dr. Reddy's Laboratories Ltd. has launched sugammadex injection in the U.S., a generic version of Merck's Bridion, expanding its hospital portfolio. This launch aligns with the first day of generic availability and aims to provide affordable, high-quality medicines for reversing neuromuscular blockade during surgery. …

Dr. Reddy’s Laboratories (NYSE: RDY) details Q1 impact from semaglutide

Dr. Reddy's Laboratories reported a 5.6% year-on-year decline in Q1 FY27 consolidated revenues, totaling ₹8,071 crores, primarily due to lower lenalidomide sales and a ₹240 crore provision for semaglutide API issues. Despite this, the base business, excluding lenalidomide, showed healthy double-digit growth across key …

ReadyTech Holdings (ASX: RDY) Wins Victorian TAFE Platform Role as Earnings Outlook Remains Under Review

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

This article first appeared on GuruFocus. Revenue: INR8,071 crores (USD853 million), a decline of 5.6% year-over-year, growth of 7.4% sequentially. EBITDA Margin: 12.5%, impacted by semaglutide API-related challenges; excluding this, margin was 15.4%. Gross Profit Margin: 46.5%, a decrease of 1,039 basis points year-over-year, …

RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories

Dr. Reddy's Laboratories slides Monday, underperforms competitors

Shares of Dr. Reddy's Laboratories Ltd. fell 0.15% to 1,150.90 Indian rupees on Monday, underperforming the broader market as the BSE SENSEX Index rose 1.02%. The company's stock closed 18.63% below its 52-week high reached on June 29th.

Nerdy Inc. Revenue Breakdown – NYSE:NRDY

Nerdy Inc. CFO Atul Bagga sells $30,233 in shares at $0.83

Nerdy Inc. CFO Atul Bagga sold 36,426 shares of the company's Class A Common Stock for $30,233 at $0.83 per share to cover tax obligations from vested restricted stock units. Following the sale, Bagga beneficially owns 1,463,574 shares. InvestingPro analysis suggests NRDY is undervalued …

NRDY|Nerdy Inc|Price:0.756|Chg%:-0.096

This article provides a detailed overview of Nerdy Inc. (NRDY) stock, including its current market trends, real-time quotes, and related analysis. It highlights the company's healthy fundamentals and high growth potential, despite recent weak stock performance, and notes that analysts rate it as a …

ReadyTech Holdings Limited

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

Levi & Korsinsky is investigating Dr. Reddy's Laboratories (RDY) after its shares dropped approximately 9% following the Q1 FY27 earnings report. The company reported a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investors who suffered financial losses due …

Dr. Reddy's Laboratories Limited Appoints Mr. Srikanth Velamakanni as an Independent Director

Dr. Reddy's Laboratories Limited announced the appointment of Mr. Srikanth Velamakanni as an Independent Director for a term of five years, effective from July 1, 2026, to June 30, 2031. Mr. Velamakanni is a notable technology leader, co-founder and Group Chief Executive of Fractal, …

Dr. Reddy’s Laboratories (NYSE: RDY) clears dividend, auditor and director moves at AGM

Dr. Reddy's Laboratories held its 42nd Annual General Meeting on July 23, 2026, where shareholders approved all resolutions, including a final dividend of Rs. 8 per equity share. Key approvals also covered the re-appointment of Mr. K Satish Reddy as director, the appointment of …

Dr. Reddy’s Laboratories (NYSE: RDY) adds independent director and appoints Deloitte

Dr. Reddy's Laboratories shareholders approved the re-appointment of Dr. K P Krishnan and the appointment of Mr. Srikanth Velamakanni as Independent Directors, each for a five-year term. Additionally, M/s Deloitte Haskins & Sells LLP was appointed as the company's Statutory Auditors for five consecutive …

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

Dr. Reddy's Laboratories (RDY) reported Q1 fiscal 2027 adjusted earnings of 6 cents per ADS, missing the Zacks Consensus Estimate of 17 cents, and revenues declined 6% year-over-year to $853 million, also missing estimates. The miss was primarily due to lower global generics revenues, …

Dr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings miss

US House adopts $95 billion Iran war funding plan; Dr Reddy’s falls 7%, and more

The US House has adopted a $95 billion Republican-only budget proposal to fund the Iran war and other White House priorities. Meanwhile, in India, Dr. Reddy's Laboratories shares fell 7% after a weaker-than-expected June quarter, and Godrej Capital has entered the gold loan business. …

Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes

Shares of Indian drugmaker Dr Reddy's Laboratories fell on Thursday after brokerages cut earnings forecasts due to weaker-than-expected quarterly results and ongoing semaglutide supply disruptions. Analysts expressed concerns about profitability, linking recovery to the successful restart of semaglutide supplies and the timely approval of …

Dr. Reddy's Starts Year on Weak Ground as Lenalidomide and Semaglutide Impacts Weigh on Results

Dr. Reddy's, a leading generic drug manufacturer, has begun the year on a weak note due to the impact of reduced lenalidomide sales and challenges from semaglutide. The company's business strategy focuses on shifting its pipeline towards complex generics, which are more difficult to …

Dr. Reddy’s Laboratories (NYSE: RDY) Q1 FY27 results and API hit

Dr. Reddy's Laboratories reported a 6% year-on-year decline in Q1 FY27 consolidated revenue to ₹80,705 Mn, with profit after tax dropping 69% to ₹4,435 Mn. The decline was heavily influenced by sharply lower lenalidomide revenues and a significant ₹2,397 Mn provision for semaglutide API. …

Earnings call transcript: Dr. Reddy’s misses Q1 2026 EPS forecast as stock falls 8%

Dr. Reddy's Laboratories reported Q1 2026 earnings and revenue that missed Wall Street expectations, primarily due to semaglutide-related costs and reduced lenalidomide sales, leading to an 8% stock decline. Despite these setbacks and margin pressures, the company's underlying base business showed double-digit growth across …

[6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)

DR. REDDY'S LABORATORIES LIMITED has filed a Form 6-K Current Report with the SEC for July 2026. This report, accepted by EDGAR on July 22, 2026, includes an intimation dated July 22, 2026, as Exhibit 99.1. The pharmaceutical company, based in Hyderabad, India, confirms …

Dr Reddy's Q1 profit plunges 69% as semaglutide API issue, lenalidomide transition weigh

Dr. Reddy's Laboratories reported a significant 69% year-on-year decline in consolidated net profit for the June quarter, primarily due to an expected moderation in lenalidomide revenues and a one-time provision related to a semaglutide API issue. Despite these setbacks, the company's underlying base business …

Dr Reddy's appoints Dr. Sridevi Khambhampaty as Global Head of Biologics

Dr. Reddy's Laboratories Ltd. announced the appointment of Dr. Sridevi Kh

Dr Reddy's Q1 Results: Profit Plummets Two-Third As Margins Shrink, Revenue Falls 6%

Dr Reddy's Laboratories Ltd reported a significant decline in its first-quarter earnings, with consolidated net profit plunging nearly 69% year-on-year to Rs 444 crore, missing analyst estimates. Revenue from operations also fell 5.5% to Rs 8,100 crore, while EBITDA dropped over 60%, and EBITDA …

Doctor Reddy's: Fiscal Q1 Earnings Snapshot

Dr. Reddy's Laboratories Ltd. reported earnings of $47 million in its fiscal first quarter, with a profit of 6 cents per share. The pharmaceutical company generated $853 million in revenue for the period. This financial summary was generated using data from Zacks Investment Research.

Dr. Reddy's Laboratories (NYSE:RDY) Sets New 12-Month Low - Time to Sell?

Dr. Reddy's Laboratories (RDY) Stock Falls on Q4 2026 Earnings

Dr. Reddy’s Laboratories has filed a Form 6-K with the SEC to announce that audio recordings of its earnings call for the quarter ended June 30, 2026, are now available online. The earnings call was conducted on July 22, 2026, and the web link …

Dr. Reddy's Laboratories (NYSE:RDY) Issues Quarterly Earnings Results

Dr. Reddy’s Laboratories (NYSE: RDY) posts Rs.4.3B profit amid weaker US sales

Dr. Reddy's Laboratories falls Wednesday, underperforms market

Shares of Dr. Reddy's Laboratories Ltd. dropped 1.95% on Wednesday, closing at 1,183.00 Indian rupees. This performance underperformed the broader market, as the BSE SENSEX Index fell 0.92%. The company's shares are now 16.36% below their 52-week high reached on June 29th.

Nerdy chief accounting officer Kyle Callaway sells $11,102 in stock By Investing.com

Nerdy's chief accounting officer, Kyle Callaway, sold 13,377 shares of Class A Common Stock worth $11,102 to cover tax obligations from vested restricted stock units. This transaction occurred on July 16, 2026, with shares sold at $0.83 each. Despite a 49% stock decline over …

Nerdy chief operating officer John Paszterko sells $25,758 in shares

Nerdy Inc.'s Chief Operating Officer, John Andrew Paszterko, sold 31,034 shares of the company's Class A Common Stock for $25,758 to cover tax obligations from vested restricted stock units. This transaction occurred on July 16, 2026, with shares sold at $0.83 each. Despite recent …

Nerdy chief legal officer Swenson sells $18,846 in stock

Nerdy Inc.'s Chief Legal Officer, Christopher C. Swenson, sold 22,707 shares of Class A Common Stock for $18,846 on July 16, 2026, to cover tax obligations from vested restricted stock units. Despite the sale, which was part of an automatic sell-to-cover program, Swenson still …

Form 4 Nerdy Inc For: 21 July By Investing.com

This article announces the filing of Form 4 for Nerdy Inc. (NRDY) on July 21. It indicates that the company's stock has seen a 1.83% increase. The content provided is minimal, primarily serving as a notification of the SEC filing.

Dr. Reddy's Laboratories slides Tuesday, underperforms competitors

Dr. Reddy's Laboratories Ltd. (500124) shares declined by 1.37% on Tuesday, closing at 1,206.55 Indian rupees, underperforming a broader market decline. The company's stock is now 14.70% below its 52-week high reached on June 29th. The BSE SENSEX Index also fell by 0.31%.